Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
PRINCETON, N.J., Dec. 22, 2016 -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company, announced today that its Chief Executive Officer, Al Altomari will present at the 35th Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2017 at 11:30 AM Pacific Time. The conference will be held at the Westin St. Francis in San Francisco, CA.
To access the live and archived webcasts of the presentation, visit the Investor Relations section of Agile Therapeutics website at www.agiletherapeutics.com. The webcast will be archived on Agile Therapeutics website for 60 days following the event.
About Agile
Agile Therapeutics is a women’s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products. Our product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability. For more information, please visit the company website at www.agiletherapeutics.com.
Contact: Mary Coleman 609-683-1880
